Active Pharmaceutical Ingredients


	Active Pharmaceutical Ingredients

TAPI (Teva's Active Pharmaceutical Ingredients Division)

With over 70 years of experience and over $1.4 Billion in annual sales, TAPI (Teva Active Pharmaceutical Ingredients) is an established supply leader in the global pharmaceutical market.
TAPI is a stand alone business unit of Teva Pharmaceutical Industries Limited.

Currently offering over 270 active pharmaceutical ingredients, TAPI covers a broad spectrum of products for the worldwide pharmaceutical industry. In our portfolio you can find active pharmaceutical ingredients that became generic a long time ago like Clobetasol Propionate and on the other products that will become generic in the future like Clopidogrel Bisulfate.

The R&D group at TAPI boasts a dedicated team of over 500 top scientists specializing in the fields of chemical synthesis fermentation, high potency ( e.g. Capecitabine and Drospirenone), plant extract, synthetic peptides, vitamin D derivatives, prostaglandins, analytical and solid state research and development.

With R&D centers located in Israel, Hungary, Italy, Mexico, India and the Czech Republic, TAPI generates a steady flow of API products enabling the timely introduction of pharmaceutical products to the market.

The in-house expert patent department at TAPI specializes in freedom of operation and IP prosecution. With over 20 years of patent litigation experience, TAPI’s patent department has shown outstanding effectiveness in product and process clearance.

TAPI equips its18 production facilities with cutting-edge technologies and state-of-the art computerized systems to maintain its consistently high product quality, while continuously improving productivity and reliability.

Our advanced technology and our experts in the field of solid state enable us to deliver customized particle size distribution (PSD), bulk density, specific surface area and more through process control and a variety of milling equipment. We incorporate such technologies in order to produce APIs for advanced drug delivery systems like in case of Diltiazem Hydrochloride.

Legal Note: Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e)(1).